OCUL

NASDAQ · Pharmaceuticals

Ocular Therapeutix Inc

Mid-Cap Stocks Stocks Under $10 Pharmaceutical Stocks Healthcare Stocks

$9.43

-0.21 (-2.18%)

As of Jun 21, 10:04 PM ET ·

OCUL News1 articles

Oculis Shares Plunge as Eye Drop Fails Key Trial Goal

Oculis shares tumbled 23.4% after two Phase 3 trials of OCS-01 eye drops for diabetic macular edema failed to meet the main vision goal. The company will not pursue U.S. approval for this indication.